Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility

Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
Home Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P. Natrol Appoints Vincent Andrich VP Sales for Prolab Division Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results Body Shop Reports 24.8 Mil Euro Sales Revenues Supplement Group Targets Consumer Education Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO drugstore.com Expects to Reach Profitability Target in 2003 Human Genome Project Leads to Innovative Healthcare NPIcenter’s Career Center targets nutraceutical Industry Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Editorial: An Exercise in Synergy NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway Natural Health Trends Corp. Launches Lexxus Taiwan New TrimFit® Bars Redefine Energy Bar Category New TrimFit® Bars Redefine Energy Bar Category Probiata® Offers Safe, Natural and Effective Alternative Alive & Well with Michelle Harris Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com Consumers Search for Healthy Cleaning Products That Work Nordic Naturals: Omega 3 Fatty Acids Cyanotech Names Bob Capelli as Director of Sales Nutraceutical Clinical Laboratories International, Inc., Secures $2 Million in Funding KAVA ADVISORY: Health Canada is advising consumers not to use any products containing kava Larch arabinogalactan from Larix laricina and Larix occidentalis has been approved by the Australian Authorities and is now listed as Therapeutic Goods The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza’s active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams. Larch arabinogalactan from Larix laricina and Larix occidentalis has been approved by the Australian Authorities and is now listed as Therapeutic Goods The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza’s active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams. Larch arabinogalactan from Larix laricina and Larix occidentalis has been approved by the Australian Authorities and is now listed as Therapeutic Goods The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza’s active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams. Larch arabinogalactan from Larix laricina and Larix occidentalis has been approved by the Australian Authorities and is now listed as Therapeutic Goods The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza’s active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams. IADSA workshop keeps the focus on Latin America Regulators from Argentina, Chile and Brazil have taken part in workshop in Argentina organised by the International Alliance of Dietary/Food Supplement Associations (IADSA) to address global, regional and national regulatory trends. Held last month in Buenos Aires, the workshop gave the representatives the opportunity to learn about other regulatory systems in the area of dietary supplements. IADSA workshop keeps the focus on Latin America Regulators from Argentina, Chile and Brazil have taken part in workshop in Argentina organised by the International Alliance of Dietary/Food Supplement Associations (IADSA) to address global, regional and national regulatory trends. Held last month in Buenos Aires, the workshop gave the representatives the opportunity to learn about other regulatory systems in the area of dietary supplements. Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names. Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names. Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names. Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names. Defendants in International Spam Operation Settle FTC Charges; New Canadian Defendants Identified Defendants in an operation that sold bogus weight loss supplements through illegal spam e-mail have settled Federal Trade Commission charges that their operation violated federal laws. The settlement bars them from making false or unsubstantiated claims about health benefits of any food, drug, or dietary supplements; bars violations of the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003, known as the CAN-SPAM Act; and requires them to give up $29,000 in ill-gotten gains. Defendants in International Spam Operation Settle FTC Charges; New Canadian Defendants Identified Defendants in an operation that sold bogus weight loss supplements through illegal spam e-mail have settled Federal Trade Commission charges that their operation violated federal laws. The settlement bars them from making false or unsubstantiated claims about health benefits of any food, drug, or dietary supplements; bars violations of the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003, known as the CAN-SPAM Act; and requires them to give up $29,000 in ill-gotten gains. Clarinol(TM) CLA: Now GRAS-Approved Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status. Clarinol(TM) CLA: Now GRAS-Approved Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status. Clarinol(TM) CLA: Now GRAS-Approved Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status. Clarinol(TM) CLA: Now GRAS-Approved Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status. Clarinol(TM) CLA: Now GRAS-Approved Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status. Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient. Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient. Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient. Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient. Cognis’ Tonalin® CLA Achieves FDA GRAS Status Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232). Cognis’ Tonalin® CLA Achieves FDA GRAS Status Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232). Cognis’ Tonalin® CLA Achieves FDA GRAS Status Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232). Cognis’ Tonalin® CLA Achieves FDA GRAS Status Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232). Cognis’ Tonalin® CLA Achieves FDA GRAS Status Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232). Cognis’ Tonalin® CLA Achieves FDA GRAS Status Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232). Cognis’ Tonalin® CLA Achieves FDA GRAS Status Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232). Cognis’ Tonalin® CLA Achieves FDA GRAS Status Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232). Novel food catalogue clarity reassuring but concerns remain says EHPM European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient. Novel food catalogue clarity reassuring but concerns remain says EHPM European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient. Novel food catalogue clarity reassuring but concerns remain says EHPM European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient. Novel food catalogue clarity reassuring but concerns remain says EHPM European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient. Novel food catalogue clarity reassuring but concerns remain says EHPM European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient. Novel food catalogue clarity reassuring but concerns remain says EHPM European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient. EAS Gives Regulatory Crash Course International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels. EAS Gives Regulatory Crash Course International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels. EAS Gives Regulatory Crash Course International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels. EAS Gives Regulatory Crash Course International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels. EAS Gives Regulatory Crash Course International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels. EAS Gives Regulatory Crash Course International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels. Health claims based only on human intervention studies not practical says IADSA Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’. Health claims based only on human intervention studies not practical says IADSA Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’. Health claims based only on human intervention studies not practical says IADSA Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’. Health claims based only on human intervention studies not practical says IADSA Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’. Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million. Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million. Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million. Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million. Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million. Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million. Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million. Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million. Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million. Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million. Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million. FDA Announces a Final Rule in Regards to Soluble Fiber Sources The Food and Drug Administration (FDA) is adopting as a final rule, without change, the provisions of the interim final rule (IFR) that amended the regulation authorizing a health claim on soluble fiber from certain foods and risk of coronary heart disease (CHD), to add barley betafiber as an additional eligible source of beta-glucan soluble fiber. FDA is taking this action to complete the rulemaking initiated with the IFR. FDA Announces a Final Rule in Regards to Soluble Fiber Sources The Food and Drug Administration (FDA) is adopting as a final rule, without change, the provisions of the interim final rule (IFR) that amended the regulation authorizing a health claim on soluble fiber from certain foods and risk of coronary heart disease (CHD), to add barley betafiber as an additional eligible source of beta-glucan soluble fiber. FDA is taking this action to complete the rulemaking initiated with the IFR. FDA Announces a Final Rule in Regards to Soluble Fiber Sources The Food and Drug Administration (FDA) is adopting as a final rule, without change, the provisions of the interim final rule (IFR) that amended the regulation authorizing a health claim on soluble fiber from certain foods and risk of coronary heart disease (CHD), to add barley betafiber as an additional eligible source of beta-glucan soluble fiber. FDA is taking this action to complete the rulemaking initiated with the IFR. FDA Announces a Final Rule in Regards to Soluble Fiber Sources The Food and Drug Administration (FDA) is adopting as a final rule, without change, the provisions of the interim final rule (IFR) that amended the regulation authorizing a health claim on soluble fiber from certain foods and risk of coronary heart disease (CHD), to add barley betafiber as an additional eligible source of beta-glucan soluble fiber. FDA is taking this action to complete the rulemaking initiated with the IFR. FDA Announces a Final Rule in Regards to Soluble Fiber Sources The Food and Drug Administration (FDA) is adopting as a final rule, without change, the provisions of the interim final rule (IFR) that amended the regulation authorizing a health claim on soluble fiber from certain foods and risk of coronary heart disease (CHD), to add barley betafiber as an additional eligible source of beta-glucan soluble fiber. FDA is taking this action to complete the rulemaking initiated with the IFR. FDA Announces a Final Rule in Regards to Soluble Fiber Sources The Food and Drug Administration (FDA) is adopting as a final rule, without change, the provisions of the interim final rule (IFR) that amended the regulation authorizing a health claim on soluble fiber from certain foods and risk of coronary heart disease (CHD), to add barley betafiber as an additional eligible source of beta-glucan soluble fiber. FDA is taking this action to complete the rulemaking initiated with the IFR. FDA Announces a Final Rule in Regards to Soluble Fiber Sources The Food and Drug Administration (FDA) is adopting as a final rule, without change, the provisions of the interim final rule (IFR) that amended the regulation authorizing a health claim on soluble fiber from certain foods and risk of coronary heart disease (CHD), to add barley betafiber as an additional eligible source of beta-glucan soluble fiber. FDA is taking this action to complete the rulemaking initiated with the IFR. Four "Hi-Tech Pharmaceuticals" Case Defendants Plead Guilty to Importing and Distributing "Knock-Off" Prescription Drugs Four men based in Georgia, USA, have plead guilty to conspiring to import and distribute adulterated, mislabeled and unapproved new drugs, and to commit mail and wire fraud. Four "Hi-Tech Pharmaceuticals" Case Defendants Plead Guilty to Importing and Distributing "Knock-Off" Prescription Drugs Four men based in Georgia, USA, have plead guilty to conspiring to import and distribute adulterated, mislabeled and unapproved new drugs, and to commit mail and wire fraud. EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction. EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction. EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction. EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction. EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Another Reason to Choose Healthy Lifestyle Habits Another Reason to Choose Healthy Lifestyle Habits	Capsugel, a global leader in dosage form development and manufacturing, has received certification from the Therapeutic Goods Administration (TGA), a division of the Australian Department of Health and Ageing, for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA). The TGA is Australia’s principal regulatory authority for all therapeutic goods, including pharmaceuticals, dietary and nutritional supplements, as well as complementary medicines. Lawful sale of such products in Australia requires that the product is included on the Australian Register of Therapeutic Goods (ARTG). To obtain certification, which is product-specific, a marketer must demonstrate compliance with TGA requirements. One such requirement is that the manufacturing operations used to produce the product meet the current Australian Code of Good Manufacturing Practice (GMP) for Medicinal Products. “The Australian GMP code is very thorough because it covers all medicines and is highly respected by many regulatory authorities around the world. In conjunction with the growing demand for products that utilize the Licaps liquid delivery system, our customers can now more readily access important global markets. Certainly, our experience is that the important benefits of the Licaps delivery system, which include heightened consumer preference and improved bioavailability, address global needs,” said Robert Whitelaw, Director of Sales, Marketing and Business Development for Capsugel’s Americas Region. With this TGA certification in place for a key manufacturing operation, marketers can more readily expand their product lines delivered via the Licaps technology into the Australian market – as well as elsewhere around the world because of the certification’s high credibility. “Capsugel is well positioned with the resources to help customers develop TGA certified products,” Whitelaw concluded. ******************************************* Capsugel, a world leader in dosage form development and manufacturing, produces two-piece gelatin and vegetarian capsules for nutraceutical, pharmaceutical and over-the-counter (OTC) markets. The Capsugel product line of uniquely designed and patented products includes Licaps® liquid capsules, Vcaps® and Vcaps® Plus vegetarian capsules, and DBcaps® capsules for double-blind clinical trials. The company also customizes liquid-fill formulas with laboratories in both the US and Europe. Capsugel is a division of Pfizer Inc. For more information visit www.capsugel.com or call (888) 783-6361.
Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software